8-K: Citius Pharmaceuticals Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals announced its fiscal second quarter 2025 financial results, highlighting progress towards the planned launch of LYMPHIR and ongoing efforts to secure financing.

Summary

• Citius Pharmaceuticals reported its financial results for the fiscal second quarter ended March 31, 2025.
• The company is focused on launching LYMPHIR and securing financing for its launch strategy.
• A submission to the FDA is being prepared for the Mino-Lok program based on agency feedback.
• The Phase 3 trial for Mino-Lok met its primary endpoints.
• The company completed a registered direct offering and amended its license agreement with Eisai to strengthen its financial position.
• Net proceeds of $6 million were received from equity issuance during the six months ended March 31, 2025.
• A registered direct offering closed on April 2, 2025, providing net proceeds of approximately $1.735 million.
• As of March 31, 2025, the company had $26,410 in cash and cash equivalents and 8,760,649 common shares outstanding.
• Additional capital will be needed to support operations beyond May 2025.
• Citius Oncology has retained Jefferies LLC to evaluate strategic alternatives.
• R&D expenses were $3.8 million for the quarter and $5.9 million for the six months ended March 31, 2025.
• LYMPHIR-related R&D costs increased due to expenses for a drug substance batch.
• G&A expenses were $4.8 million for the quarter and $10.2 million for the six months ended March 31, 2025, primarily due to pre-launch commercial activities for LYMPHIR.
• Net loss was $11.5 million, or ($1.27) per share, for the quarter and $21.8 million for the six months ended March 31, 2025.
• The company owns 92% of Citius Oncology.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the company's low cash position, need for additional financing, and increased net loss, although there are positives such as FDA approval of LYMPHIR and progress with Mino-Lok.

Positives

• LYMPHIR received FDA approval in August 2024.
• The Phase 3 trial for Mino-Lok met its primary endpoints.
• The company is actively engaged with the FDA regarding next steps for Mino-Lok and Halo-Lido.
• Citius Oncology has retained Jefferies LLC to evaluate strategic alternatives to maximize stockholder value.
• The company completed a registered direct offering and amended its license agreement with Eisai to strengthen its financial position.

Negatives

• The company had only $26,410 in cash and cash equivalents as of March 31, 2025.
• Additional capital will be needed to support operations beyond May 2025.
• Net loss was $11.5 million, or ($1.27) per share, for the quarter ended March 31, 2025.
• Net loss was $21.8 million for the six months ended March 31, 2025.

Risks

• The company needs substantial additional funds to fund operations beyond May 2025.
• The company's ability to commercialize LYMPHIR is subject to risks.
• The company's ability to maintain compliance with Nasdaq's continued listing standards is a risk.
• The company's dependence on third-party suppliers is a risk.
• Uncertainties relating to preclinical and clinical testing pose a risk.

Future Outlook

The company is focused on the planned launch of LYMPHIR and is actively engaged in securing the necessary financing to advance its launch strategy, as well as exploring strategic partners for Citius Oncology; research and development expenses will continue to decrease in fiscal 2025 as the company continues to focus on the commercialization of LYMPHIR and because they have completed the Phase 3 trial for Mino-Lok.

Management Comments

• As we continue to focus on the planned launch of our first FDA-approved product, LYMPHIR, through Citius Oncology, we are actively engaged in securing the necessary financing to advance our launch strategy in the coming months, as well as exploring strategic partners for Citius Oncology, said Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals and Citius Oncology.
• We are also in the process of preparing a submission to the FDA that reflects the valuable feedback we received from the agency concerning clinical efficacy, safety data, and in-vitro data.
• This submission is a key step toward supporting a future New Drug Application (NDA) for our Mino-Lok program.
• As a reminder, our Phase 3 Trial, which was completed last year, met its primary endpoints, added Mazur.
• With these efforts underway, we believe we are positioned to deliver long-term value to patients and shareholders alike, concluded Mazur.

Industry Context

Citius Pharma is operating in the competitive biopharmaceutical industry, focusing on critical care products and oncology. The company's focus on LYMPHIR and Mino-Lok aligns with the growing demand for targeted immunotherapies and solutions for catheter-related bloodstream infections.

Comparison to Industry Standards

• It's difficult to compare Citius Pharma's financial results directly to industry standards without knowing the specific stage of development and product focus of comparable companies.
• However, R&D expenses as a percentage of revenue (since there is no revenue yet) are a key metric to watch, and the company's ability to secure financing and strategic partnerships will be crucial for its long-term success.
• Companies like Amgen and Gilead Sciences spend significantly on R&D, but they also have established revenue streams to support these investments.

Stakeholder Impact

• Shareholders face potential dilution due to the need for additional capital.
• Employees' job security could be affected by the company's financial situation.
• Patients could benefit from the launch of LYMPHIR and the potential approval of Mino-Lok.
• Suppliers and creditors face increased risk due to the company's financial situation.

Next Steps

• The company will continue to focus on the planned launch of LYMPHIR.
• The company will continue to seek financing to support its operations.
• The company will prepare a submission to the FDA for the Mino-Lok program.
• Citius Oncology will evaluate strategic alternatives to maximize stockholder value.

Key Dates

Keywords

LYMPHIR, Mino-Lok, Citius Pharmaceuticals, Financial Results, FDA, R&D, Financing, CTXR, Oncology